

Appendix

Potential target patient populations 2019

Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience


Immunology

Herceptin + Perjeta, Tecentriq: *HER2+ early Breast Cancer (eBC)*



Perjeta, Herceptin, Kadcylla, Tecentriq: *HER2+ metastatic Breast Cancer (mBC)*


- The target US and EU 5 population for **1L HER2+ mBC** is **~19,500 patients (7,700 de novo and 11,800 adjuvant relapse)**
- The target US and EU 5 population for **2L-4L HER2+ mBC** is **~26,700 patients (~11,100 US/~15,600 Top 5 EU)**



	Adjuvant Relapse	de novo
1L Patients (Top 5 EU)	7,000	3,700
1L Patients (US)	4,800	4,000
HER2+ Rx opportunities Drug treated patients		
	US	5 EU
1L	4,800	7,000
2L	6,000	7,800
3L	3,600	5,800
4L	1,500	2,000


Ipatasertib:

HER2-/HR+ 1L and recurrent mBC




Source: Roche/Genentech; *2/3L includes HR+ patients who received chemotherapy in 1L; Patients may receive up to 7 lines of treatment, but 4L+ patients are not included; Ipatasertib in collaboration with Array BioPharma


Tecentriq, ipatasertib: Triple Negative Breast Cancer (TNBC)



Avastin: Ovarian Cancer (OC)




Tecentriq, Avastin: Non Squamous Non Small Cell Lung Cancer (NSq NSCLC)




Alecensa:

ALK+ metastatic Non Small Cell Lung Cancer (mNSCLC)




Tecentriq: Small Cell Lung Cancer (SCLC)




Zelboraf:

Adjuvant BRAF+ stage IIc and III Melanoma




Zelboraf:

1L BRAF+ metastatic Melanoma (mM)




Erivedge:

Advanced Basal Cell Carcinoma (BCC)




Avastin: Colorectal Cancer (CRC)

- The target population for Avastin in 1L CRC is ~238,000 patients and in 2L CRC ~128,100 patients




Tecentriq:

Adjuvant Muscle Invasive Bladder Cancer (MIBC)




Tecentriq:


Metastatic Urothelial Bladder Cancer (mUBC)




Tecentriq: Renal Cell Carcinoma (RCC)




Tecentriq: Hepatic Cell Carcinoma (HCC)




Gazyva, Rituxan: Indolent Non-Hodgkin's Lymphoma (iNHL)




Polatuzumab vedotin, Rituxan: Aggressive Non-Hodgkin's Lymphoma (aNHL/DLBCL)



Gazyva, Venclexta, Rituxan: Chronic Lymphocytic Leukemia (CLL)




Venclexta, idasanutlin: Acute Myeloid Leukemia (AML)



Source: Roche/Genentech; Venclexta in collaboration with AbbVie

Venclexta: Multiple Myeloma (MM)



Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience

Immunology

Hemlibra: *Hemophilia A*



Oncology

Hemophilia A


Ophthalmology

Infectious diseases


Neuroscience

Immunology


Faricimab, Port Delivery System (PDS), Lucentis: *Age-related Macular Degeneration (AMD)*



Faricimab, Port Delivery System (PDS), Lucentis: *Diabetic Macular Edema (DME)*



Port Delivery System (PDS), Lucentis: *Retinal Vein Occlusion (RVO)*



Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience

Immunology

Xofluza: Influenza A & B



Oncology

Hemophilia A


Ophthalmology

Infectious diseases


Neuroscience

Immunology


Ocrevus: Multiple Sclerosis (MS)




Risdiplam (RG7916): *Spinal Muscular Atrophy (SMA)*



Myostatin inhibiting adnectin fusion protein (RG6206): *Duchenne Muscular Dystrophy (DMD)*




HTT-ASO (RG6042): *Huntington's Disease (HD)*




Balovaptan (RG7314): *Autism Spectrum Disorder (ASD)*


There are no FDA approved pharmacologic treatments for the core symptoms of ASD so today no one is treated with a pharmacologic for the core symptoms of Autism Spectrum Disorder*




Crenezumab, gantenerumab: *Alzheimer's Disease (AD)*



Satralizumab (RG6168): *Neuromyelitis Optica (NMO)*



Prasinezumab (RG7935): *Parkinson's Disease (PD)*



Oncology

Hemophilia A

Ophthalmology


Infectious diseases

Neuroscience


Immunology

Esbriet:

Idiopathic Pulmonary Fibrosis (IPF)




Diagnosed Prevalence by Severity




Xolair:

Moderate to severe Asthma





Xolair: *Nasal Polyps*




Actemra, Rituxan: Rheumatoid Arthritis (RA)

Global target population for Actemra and Rituxan in rheumatoid arthritis is ~1.2M biologics eligible patients.

US Biologic treated patients by line of therapy




Actemra: Systemic Juvenile Idiopathic Arthritis (sJIA)




Actemra:


Polyarticular Juvenile Idiopathic Arthritis (pJIA)




Actemra: Giant Cell Arteritis (GCA)




Etrolizumab: *Ulcerative Colitis (UC)*



Etrolizumab: *Crohn's Disease (CD)*



Gazyva: *Lupus Nephritis (LN)*



Doing now what patients need next